Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma - Long-term results of phase III RTOG 85-31

Miljenko V. Pilepich, Kathryn Winter, Colleen A. Lawton, Robert E. Krisch, Harvey B. Wolkov, Benjamin Movsas, Eugen B. Hug, Sucha O. Asbell, David Grignon

Research output: Contribution to journalArticle

706 Citations (Scopus)

Abstract

Purpose: Radiation Therapy Oncology Group protocol 85-31 was designed to evaluate the effectiveness of adjuvant androgen suppression, using goserelin, in unfavorable prognosis carcinoma of the prostate treated with definitive radiotherapy (RT). Methods and Materials: Eligible patients were those with palpable primary tumor extending beyond the prostate (clinical Stage T3) or those with regional lymphatic involvement. Patients who had undergone prostatectomy were eligible if penetration through the prostatic capsule to the margin of resection and/or seminal vesicle involvement was documented histologically. Stratification was based on histologic differentiation, nodal status, acid phosphatase status, and prior prostatectomy. The patients were randomized to either RT and adjuvant goserelin (Arm I) or RT alone followed by observation and application of goserelin at relapse (Arm II). In Arm I, the drug was to be started during the last week of RT and was to be continued indefinitely or until signs of progression. Results: Between 1987 and 1992, when the study was closed, 977 patients were entered: 488 to Arm I and 489 to Arm II. As of July 2003, the median follow-up for all patients was 7.6 years and for living patients was 11 years. At 10 years, the absolute survival rate was significantly greater for the adjuvant arm than for the control arm: 49% vs. 39%, respectively (p = 0.002). The 10-year local failure rate for the adjuvant arm was 23% vs. 38% for the control arm (p

Original languageEnglish (US)
Pages (from-to)1285-1290
Number of pages6
JournalInternational Journal of Radiation Oncology Biology Physics
Volume61
Issue number5
DOIs
StatePublished - Apr 1 2005
Externally publishedYes

Fingerprint

Androgens
Prostate
radiation therapy
Radiotherapy
cancer
Goserelin
retarding
Carcinoma
Prostatectomy
Adjuvant Radiotherapy
Radiation Oncology
phosphatases
prognosis
Seminal Vesicles
capsules
Acid Phosphatase
stratification
progressions
Capsules
margins

Keywords

  • Androgen ablation
  • Prostate cancer
  • Radiotherapy

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Radiation

Cite this

Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma - Long-term results of phase III RTOG 85-31. / Pilepich, Miljenko V.; Winter, Kathryn; Lawton, Colleen A.; Krisch, Robert E.; Wolkov, Harvey B.; Movsas, Benjamin; Hug, Eugen B.; Asbell, Sucha O.; Grignon, David.

In: International Journal of Radiation Oncology Biology Physics, Vol. 61, No. 5, 01.04.2005, p. 1285-1290.

Research output: Contribution to journalArticle

Pilepich, Miljenko V. ; Winter, Kathryn ; Lawton, Colleen A. ; Krisch, Robert E. ; Wolkov, Harvey B. ; Movsas, Benjamin ; Hug, Eugen B. ; Asbell, Sucha O. ; Grignon, David. / Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma - Long-term results of phase III RTOG 85-31. In: International Journal of Radiation Oncology Biology Physics. 2005 ; Vol. 61, No. 5. pp. 1285-1290.
@article{34fb13924ea64a22a7a9ecc31f9628f3,
title = "Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma - Long-term results of phase III RTOG 85-31",
abstract = "Purpose: Radiation Therapy Oncology Group protocol 85-31 was designed to evaluate the effectiveness of adjuvant androgen suppression, using goserelin, in unfavorable prognosis carcinoma of the prostate treated with definitive radiotherapy (RT). Methods and Materials: Eligible patients were those with palpable primary tumor extending beyond the prostate (clinical Stage T3) or those with regional lymphatic involvement. Patients who had undergone prostatectomy were eligible if penetration through the prostatic capsule to the margin of resection and/or seminal vesicle involvement was documented histologically. Stratification was based on histologic differentiation, nodal status, acid phosphatase status, and prior prostatectomy. The patients were randomized to either RT and adjuvant goserelin (Arm I) or RT alone followed by observation and application of goserelin at relapse (Arm II). In Arm I, the drug was to be started during the last week of RT and was to be continued indefinitely or until signs of progression. Results: Between 1987 and 1992, when the study was closed, 977 patients were entered: 488 to Arm I and 489 to Arm II. As of July 2003, the median follow-up for all patients was 7.6 years and for living patients was 11 years. At 10 years, the absolute survival rate was significantly greater for the adjuvant arm than for the control arm: 49{\%} vs. 39{\%}, respectively (p = 0.002). The 10-year local failure rate for the adjuvant arm was 23{\%} vs. 38{\%} for the control arm (p",
keywords = "Androgen ablation, Prostate cancer, Radiotherapy",
author = "Pilepich, {Miljenko V.} and Kathryn Winter and Lawton, {Colleen A.} and Krisch, {Robert E.} and Wolkov, {Harvey B.} and Benjamin Movsas and Hug, {Eugen B.} and Asbell, {Sucha O.} and David Grignon",
year = "2005",
month = "4",
day = "1",
doi = "10.1016/j.ijrobp.2004.08.047",
language = "English (US)",
volume = "61",
pages = "1285--1290",
journal = "International Journal of Radiation Oncology Biology Physics",
issn = "0360-3016",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma - Long-term results of phase III RTOG 85-31

AU - Pilepich, Miljenko V.

AU - Winter, Kathryn

AU - Lawton, Colleen A.

AU - Krisch, Robert E.

AU - Wolkov, Harvey B.

AU - Movsas, Benjamin

AU - Hug, Eugen B.

AU - Asbell, Sucha O.

AU - Grignon, David

PY - 2005/4/1

Y1 - 2005/4/1

N2 - Purpose: Radiation Therapy Oncology Group protocol 85-31 was designed to evaluate the effectiveness of adjuvant androgen suppression, using goserelin, in unfavorable prognosis carcinoma of the prostate treated with definitive radiotherapy (RT). Methods and Materials: Eligible patients were those with palpable primary tumor extending beyond the prostate (clinical Stage T3) or those with regional lymphatic involvement. Patients who had undergone prostatectomy were eligible if penetration through the prostatic capsule to the margin of resection and/or seminal vesicle involvement was documented histologically. Stratification was based on histologic differentiation, nodal status, acid phosphatase status, and prior prostatectomy. The patients were randomized to either RT and adjuvant goserelin (Arm I) or RT alone followed by observation and application of goserelin at relapse (Arm II). In Arm I, the drug was to be started during the last week of RT and was to be continued indefinitely or until signs of progression. Results: Between 1987 and 1992, when the study was closed, 977 patients were entered: 488 to Arm I and 489 to Arm II. As of July 2003, the median follow-up for all patients was 7.6 years and for living patients was 11 years. At 10 years, the absolute survival rate was significantly greater for the adjuvant arm than for the control arm: 49% vs. 39%, respectively (p = 0.002). The 10-year local failure rate for the adjuvant arm was 23% vs. 38% for the control arm (p

AB - Purpose: Radiation Therapy Oncology Group protocol 85-31 was designed to evaluate the effectiveness of adjuvant androgen suppression, using goserelin, in unfavorable prognosis carcinoma of the prostate treated with definitive radiotherapy (RT). Methods and Materials: Eligible patients were those with palpable primary tumor extending beyond the prostate (clinical Stage T3) or those with regional lymphatic involvement. Patients who had undergone prostatectomy were eligible if penetration through the prostatic capsule to the margin of resection and/or seminal vesicle involvement was documented histologically. Stratification was based on histologic differentiation, nodal status, acid phosphatase status, and prior prostatectomy. The patients were randomized to either RT and adjuvant goserelin (Arm I) or RT alone followed by observation and application of goserelin at relapse (Arm II). In Arm I, the drug was to be started during the last week of RT and was to be continued indefinitely or until signs of progression. Results: Between 1987 and 1992, when the study was closed, 977 patients were entered: 488 to Arm I and 489 to Arm II. As of July 2003, the median follow-up for all patients was 7.6 years and for living patients was 11 years. At 10 years, the absolute survival rate was significantly greater for the adjuvant arm than for the control arm: 49% vs. 39%, respectively (p = 0.002). The 10-year local failure rate for the adjuvant arm was 23% vs. 38% for the control arm (p

KW - Androgen ablation

KW - Prostate cancer

KW - Radiotherapy

UR - http://www.scopus.com/inward/record.url?scp=16344385883&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=16344385883&partnerID=8YFLogxK

U2 - 10.1016/j.ijrobp.2004.08.047

DO - 10.1016/j.ijrobp.2004.08.047

M3 - Article

C2 - 15817329

AN - SCOPUS:16344385883

VL - 61

SP - 1285

EP - 1290

JO - International Journal of Radiation Oncology Biology Physics

JF - International Journal of Radiation Oncology Biology Physics

SN - 0360-3016

IS - 5

ER -